Opendata, web and dolomites

P-TEV TERMINATED

Personalized Tissue-Engineered Veins as the first Cure for Patients with Chronic Venous Insufficiency

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 P-TEV project word cloud

Explore the words cloud of the P-TEV project. It provides you a very rough idea of what is the project "P-TEV" about.

blood    3d    budgetary    medical    bicuspid    subsequently    transplant    suitable    vascular    2019    rejection    chronic    healthcare    function    patient    scaffold    break    medicines    seeded    grafts    surgery    ulceration    agency    extracellular    deep    venous    intact    matrix    foreign    peripheral    found    structural    regenerative    risks    vein    cured    medicine    insufficiency    benefit    steppingstone    commercialize    paradigm    recellularization    relief    too    patients    functioning    progressive    proof    fill    acute    immunogenic    donated    personalized    clean    clinical    constitutes    personalization    cells    breakthrough    serve    valves    allogeneic    veins    vessels    treatment    grant    donor    de    allotransplantation    avoids    leg    replace    engineered    market    dysfunctional    synthetic    properly    autologous    positioned    cvi    severe    unparalleled    marketing    added    first    removing    turns    tissue    gap    replacement    gmp    small    approval    dna    tev    decellularized    verigraft    immunosuppression    stage   

Project "P-TEV" data sheet

The following table provides information about the project.

Coordinator
VERIGRAFT AB 

Organization address
address: ARVID WALLGRENS BACKE 20
city: GOTEBORG
postcode: 413 46
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.verigraft.com
 Total cost 2˙184˙603 €
 EC max contribution 2˙184˙603 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VERIGRAFT AB SE (GOTEBORG) coordinator 2˙184˙603.00

Map

 Project objective

This project will commercialize P-TEV - a unique personalized tissue engineered vein for the treatment of patients with severe Chronic Venous Insufficiency (CVI). CVI is a progressive medical condition in which the valves of the deep veins of the leg are not functioning properly. The most severe stage is CVI with leg ulceration. No effective treatment is available, and a large number of patients would directly benefit from venous vascular surgery. These patients cannot be cured today because no suitable grafts for replacement of the dysfunctional venous valves have yet been developed. There are no synthetic products which could replace the function of the bicuspid valves found in the leg veins and the risks associated with allotransplantation are too high. VERIGRAFT’s technology is the first one positioned to break this paradigm and fill the existing market gap. The technology allows the personalization of blood vessels by de- and recellularization. In short, a donated tissue is decellularized, removing all immunogenic donor cells and DNA. This results in a clean extracellular matrix scaffold with intact 3D structural properties. Subsequently, this scaffold is seeded with the patient´s own cells, derived from a small sample of peripheral blood. This unique technology turns an allogeneic (“foreign”) tissue into an autologous (“personalized”) one and thus avoids transplant rejection without the need for immunosuppression. The clinical proof-of-concept for P-TEV is established. The project will include the clinical study and GMP process development that will grant VERIGRAFT market access by 2019 and serve as a steppingstone to marketing approval by the European Medicines Agency. The EU-added value of the project is unparalleled, as it constitutes a breakthrough in one of future medicine's most promising fields – advanced personalized regenerative medicine, bringing significant long-term budgetary relief to healthcare systems.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "P-TEV" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "P-TEV" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More